Biocon has received approval from the United States Food and Drug Administration (USFDA) for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. 

Liraglutide is a synthetic analog of Glucagon-like peptide-1 (GLP-1) and is administered as a once-daily injection. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. According to IQVIA MAT December 2025 the total addressable market opportunity for GLP-1 in weight loss in the U.S. was $127 million.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.